RetinalGenix Q3: $5 Cash, Going-Concern Doubt, Note in Default
RTGN has more than doubled off its 52-week low of $0.25.
Summary
RetinalGenix reported $5 of cash at September 30, 2026, substantial doubt about going concern, a $50,000 note in default, and that it is weighing a reverse merger or asset sale. The quarter's net loss was $1.33 million.
Key Events · Legal and Risk Events · RTGN
-
Cash Down to $5
Cash was $5 at September 30, 2026 versus $14,774 at December 31, 2025, against total liabilities of $2,032,543.
-
Going-Concern Warning
Management states cash is expected to fund operations only for a few days and that substantial doubt exists about the company's ability to continue as a going concern.
-
Strategic Alternatives Under Review
The company says it is considering a reverse merger, sale of assets or other transactions, and has no definitive agreement for any strategic or capital-raising deal.
-
Note in Default
The $50,000 shareholder promissory note from July 2026 matured October 1, 2026 and was not repaid; the lender has informally agreed to extend.
Analysis · RTGN · Industrial Applications And Services
RetinalGenix ended September with $5 of cash against $2.03 million of liabilities, and management states plainly that it cannot fund operations beyond the next few days without new capital. That is a survival problem, not a growth problem: the company has no revenue, a $19.19 million accumulated deficit, and a $50,000 shareholder note already in default since its October 1, 2026 maturity. Management is now openly weighing a reverse merger or asset sale alongside a capital raise, which puts a strategic transaction — or a failure to fund — on the table. The one offset is that the August 2026 share issuance to Sanovas retired $996,007 of related-party payables, cutting the Sanovas balance to $165,375, but that was a non-cash debt-for-equity swap, not new money. A previously disclosed material weakness in internal controls (lack of segregation of duties) remains unremediated.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RTGN was trading at $3.99 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $75.2M. The 52-week trading range was $0.25 to $20.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.